FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Northwest Biotherapeutics, Inc. Stock AnalysisComprehensive stock analysis for Northwest Biotherapeutics, Inc. (NWBO) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisNWBO
NWBO
Northwest Biotherapeutics, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
NWBO
Home🔹Stocks🔹Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics, Inc.

NWBO•OTC

Northwest Biotherapeutics, Inc.

NWBO•OTC
Market cap
$359.44M
Sentiment

Your view on NWBO

Mkt Cap
$359.44M
Sentiment
Your view
NWBO
Northwest Biotherapeutics, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
NWBO
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Northwest Biotherapeutics, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Linda F. Powers
Headquarters
4800 Montgomery Lane, Bethesda, MD, US
Industry
Biotechnology
Sector
Healthcare
CEO
Linda F. Powers
Headquarters
4800 Montgomery Lane, Bethesda, MD, US
Description

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News